Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
P/E ratio for Vaxxinity, Inc. (VAXX)
P/E ratio as of 2023: -1.89
According to Vaxxinity, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.89. At the end of 2022 the company had a P/E ratio of -2.34.
P/E ratio history for Vaxxinity, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.89 |
| 2022 | -2.34 |
| 2021 | -5.10 |
| 2020 | -58.69 |
| 2019 | -146.02 |